Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

ATON

AlphaTON Capital Corp

Dec 02 • 10:43AM ET

1.70

-0.01 -0.58 %

Financial • Asset Management • United Kingdom • NASD

Peers: VRTX GILD AMGN REGN ROG BMRN BIIB BNTX EXEL INCY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-65.69	Insider Own	62.99%	Shs Outstand	6.35M	Perf Week	-37.96%
Market Cap	12.96M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.82M	Perf Month	-66.93%
Enterprise Value	10.53M	PEG	-	EPS next Q	-	Inst Own	0.62%	Short Float	4.25%	Perf Quarter	-75.04%
Income	-67.28M	P/S	-	EPS this Y	-	Inst Trans	2.22%	Short Ratio	0.08	Perf Half Y	-77.95%
Sales	0.00M	P/B	1.36	EPS next Y	-	ROA	-136.43%	Short Interest	0.12M	Perf YTD	-67.12%
Book/sh	1.25	P/C	7.37	EPS next 5Y	-	ROE	-194.84%	52W High	15.82 -89.25%	Perf Year	-59.62%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	39.50% 10.10%	ROIC	-4812.45%	52W Low	1.53 11.11%	Perf 3Y	-98.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	29.40% 15.26%	Perf 5Y	-99.31%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	48.91%	Oper. Margin	-	ATR (14)	0.52	Perf 10Y	-99.32%
Dividend Ex-Date	-	Quick Ratio	3.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	22.21	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.08	EPS Q/Q	78.19%	SMA20	-46.05%	Beta	0.30	Target Price	140.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-64.92%	Rel Volume	0.42	Prev Close	1.71
Employees	-	LT Debt/Eq	0.00	Earnings	Jul 25 AMC	SMA200	-72.75%	Avg Volume	1.51M	Price	1.70
IPO	Jan 21, 1999	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	142,784	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$26
Mar-07-22	Initiated	H.C. Wainwright	Buy	$32
Sep-21-21	Initiated	Oppenheimer	Outperform	$30
Sep-02-21	Initiated	B. Riley Securities	Buy	$40
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight	$35

Dec-01-25 08:50AM	AlphaTON Capital Successfully Deploys First Fleet of Nvidia B200 GPUs to Telegram's Cocoon AI Network, Powering Privacy-First AI for One Billion Users (GlobeNewswire) -9.52%
Nov-26-25 10:15AM	AlphaTON Capital Secures $82.5 Million Strategic GPU Infrastructure to Power Privacy-First Decentralized Artificial Intelligence Cluster after Successful Pilot Launch of Telegram's Cocoon AI (GlobeNewswire) -12.56%
09:16AM	AlphaTON Capital Announces $82.5 Million Strategic GPU Infrastructure Investment to Power Privacy-First Decentralized AI after Successful Pilot Launch of Telegram's Cocoon AI (GlobeNewswire)
Nov-25-25 08:00AM	AlphaTON Capital Corp. to Accumulate Telegram Bonds for its Treasury (GlobeNewswire) -21.53%
Nov-24-25 07:00AM	AlphaTON Capital Submits Strategic Offer to Acquire Majority Stake in Forbes Media Holdings (GlobeNewswire) -6.16%
07:18PM	Loading…
Nov-20-25 07:18PM	AlphaTON Capital (Nasdaq: ATON) Issues Shareholder Update on Balance Sheet Assets and Strategic Ecosystem Expansion Clarification and Correction (GlobeNewswire) +8.96%
09:41AM	AlphaTON Bolsters Tech Leadership with New CTO to Drive AI Growth (GlobeNewswire)
Nov-19-25 09:00AM	AlphaTON Capital (Nasdaq: ATON) Issues Shareholder Update on Balance Sheet Assets and Strategic Ecosystem Expansion (GlobeNewswire)
Nov-17-25 03:04PM	AlphaTON Capital Names P2P.org as Institutional Staking Partner to Accelerate TON Treasury Yield Strategy (GlobeNewswire)
10:31AM	AlphaTON Capital Selects P2P.org as First Institutional Staking Partner for TON Treasury Operations (GlobeNewswire)
Nov-13-25 08:09AM	AlphaTON Capital and SingularityNET Join Forces to Accelerate Telegram's Cocoon AI - Growing the Ethical, Decentralized AI Ecosystem (GlobeNewswire) -11.11%
Nov-12-25 07:00AM	AlphaTON's Cyncado Therapeutics and Australia's ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans (GlobeNewswire)
Nov-11-25 08:34AM	AlphaTON Capital Accelerates Global Growth with Strategic Appointment of William De'Ath as Chief Partnership Officer (GlobeNewswire)
Nov-07-25 07:00AM	Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado's A2B and A2A Receptor Antagonists and Cancer Vaccines (GlobeNewswire) -14.16%
Nov-05-25 06:19AM	AlphaTON Capital to Acquire Premier Crypto Newswire Blockchain Wire, Cementing Dominance in Digital Asset Communications via the Telegram Ecosystem (GlobeNewswire)
08:37PM	Loading…
Nov-04-25 08:37PM	DAT ALERT: AlphaTON Capital Acquires 300,000 additional TON (GlobeNewswire)
Nov-03-25 01:00PM	Brittany Kaiser to Present at SALT London 2025 on DeFi, Tokenization, and Digital Asset Treasuries (GlobeNewswire) -7.20%
08:00AM	AlphaTON Capital Takes Center Stage at TRUST Summit 2025 to Shape the Future of Digital Finance (GlobeNewswire)
08:00AM	AlphaTON Capital Corp Announces Strategic Joint Venture with Pago Pay and with ALT5 Sigma to Launch Crypto-Enabled TON Mastercard (GlobeNewswire)
Oct-31-25 12:55PM	AlphaTON Capital Kicks Off Global World Tour with Investor Breakfast at Nasdaq MarketSite (GlobeNewswire)
Oct-29-25 10:46AM	AlphaTON Capital Announces Strategic Investment in GPU Infrastructure to Power Cocoon Decentralized AI Network (GlobeNewswire)
Oct-27-25 08:10AM	AlphaTON Capital CEO Brittany Kaiser to Speak at "Future of Money, Governance, and the Law" Summit on Capitol Hill, October 30, 2025 (GlobeNewswire)
08:00AM	AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026 (GlobeNewswire)
Oct-25-25 12:30PM	AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4's Path to First- Patient Dosing (GlobeNewswire)
Oct-24-25 08:05AM	AlphaTON Capital Appoints Wes Levitt as Chief Financial Officer (GlobeNewswire)
Oct-23-25 04:49AM	Can Telegram Crypto Make a Come Back? TONs Corporate Treasury Plans Could See TON Price Hit $3.50 in November (99bitcoins)
Oct-22-25 12:45PM	AlphaTON Capital Joins Blockchain Game Alliance (BGA) (GlobeNewswire)
12:00PM	AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth (GlobeNewswire)
Oct-20-25 07:00AM	Enzo Villani, Chief Investment Officer of AlphaTON Capital, to Speak at the Vatican's 10th Anniversary World Changers Summit (GlobeNewswire)
Oct-15-25 08:16AM	AlphaTON Capital Powers TOKEN2049 "Origins" Hackathon in Singapore (GlobeNewswire) -8.56%
07:00AM	Loading…
Oct-14-25 07:00AM	AlphaTON Capital CEO Brittany Kaiser and SkyBridge Capital Founder Anthony Scaramucci Join Schwab Network's Trading 360 to Discuss Crypto Innovation and Cancer Research Funding (GlobeNewswire) +9.02%
Oct-13-25 07:26AM	AlphaTON Capital Launches AI Vertical with MorpheusAI to Accelerate Agentic AI Development on TON and Telegram (GlobeNewswire)
Oct-12-25 09:00PM	Market Alert: AlphaTON Capital Continues in Growth Mode and Purchases an additional 300,000 TON (GlobeNewswire)
Oct-11-25 09:48AM	Health In Tech, AlphaTON Partner to Develop 'HITChain' Blockchain Platform for Healthcare Claims on TON (Insider Monkey)
Oct-10-25 08:02AM	AlphaTON Capital Receives Nasdaq Congratulations for Groundbreaking Cancer Research Tokenization Initiative (GlobeNewswire) -24.55%
Oct-09-25 08:53AM	AlphaTON Capital CIO and Executive Chairman Enzo Villani Featured in Live Interview at Nasdaq MarketSite with IPO Edge (GlobeNewswire) -23.46%
Oct-08-25 07:16AM	AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing (GlobeNewswire) +95.52%
Oct-07-25 09:39AM	TON on Telegram Ecosystem: AlphaTON Capital CIO Enzo Villani, Live at Nasdaq (Exec Edge)
Sep-25-25 02:45PM	AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition (GlobeNewswire)
Sep-03-25 12:37PM	AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem (GlobeNewswire)
Jul-25-25 04:15PM	Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 (GlobeNewswire)
Jun-25-25 07:00AM	Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) +13.57%
Jun-09-25 06:00AM	Portage Biotech and Compedica Stock-for-Stock Exchange (GlobeNewswire) -9.63%
Apr-28-25 06:00AM	Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +27.46%
Mar-27-25 04:15PM	Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +103.82%
Mar-12-25 08:00AM	Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial (GlobeNewswire)
Feb-12-25 04:15PM	Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements (GlobeNewswire)
Jan-30-25 04:30PM	Portage Biotech Announces Completion of $2.15 Million Private Financing (GlobeNewswire)
Jan-06-25 05:00AM	Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company (GlobeNewswire)
Dec-17-24 07:00AM	Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd (GlobeNewswire) +178.15%
Dec-12-24 04:15PM	Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter (GlobeNewswire) -21.47%
Nov-26-24 04:05PM	Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 (GlobeNewswire) -13.55%
Aug-27-24 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update (GlobeNewswire)
Aug-15-24 07:00AM	Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update (GlobeNewswire) +62.79%
Aug-13-24 07:00AM	Portage Biotech Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -18.10%
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Apr-15-24 07:05AM	Immuno-oncology company Portage Biotech to evaluate strategic alternatives (Pharmaceutical Business Review) -25.27%
Apr-12-24 10:33AM	Portage Biotech previews possible closure as it halts programs, hunts for strategic options (FierceBiotech.com) -9.00%
08:01AM	Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives (GlobeNewswire)
Mar-26-24 08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire) +9.73%
Feb-28-24 05:10PM	Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update (GlobeNewswire) -15.71%
Jan-04-24 08:00AM	Portage Biotech Reports Business and Strategic Update (GlobeNewswire)
Nov-28-23 04:01PM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update (GlobeNewswire) +8.46%
Nov-06-23 08:01AM	Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-29-23 08:00AM	Portage Biotech Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -7.52%
Sep-20-23 08:00AM	Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors (GlobeNewswire) +26.81%
Aug-30-23 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update (GlobeNewswire) -13.36%
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +7.69% -7.76%
Jun-26-23 08:00AM	Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors (GlobeNewswire)
Jun-05-23 08:00AM	Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-01-23 08:00AM	Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference (GlobeNewswire) +5.17%
Apr-26-23 05:00PM	Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Portage Biotech to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.69%
Mar-01-23 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022 (GlobeNewswire)
Feb-27-23 04:05PM	Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer (GlobeNewswire) +6.94%
Feb-15-23 08:00AM	Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Nov-29-22 04:43PM	Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022 (GlobeNewswire)
Nov-10-22 09:00AM	Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-08-22 08:00AM	Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck (GlobeNewswire)
Sep-14-22 08:39AM	Portage Biotech Provides Research and Development Update (GlobeNewswire)
Sep-08-22 08:00AM	Portage Biotech to Present at Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-29-22 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022 (GlobeNewswire)
Aug-18-22 08:00AM	Portage Biotech Announces Leadership Updates (GlobeNewswire)
Aug-01-22 09:10AM	UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
Jul-20-22 09:00AM	Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform (GlobeNewswire) +6.13%
Jul-06-22 04:05PM	Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway (GlobeNewswire)
Jun-06-22 08:00AM	Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study (GlobeNewswire) -8.47%
Apr-25-22 08:00AM	Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity (GlobeNewswire) +8.33%
Apr-13-22 10:00AM	Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting (GlobeNewswire) +8.95%
Mar-31-22 08:00AM	Portage Biotech Provides Update on Clinical-Stage and Development Programs (GlobeNewswire)
Mar-09-22 09:00AM	Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-24-22 05:43PM	Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year (GlobeNewswire) +13.79%
Feb-15-22 08:00AM	Portage Biotech Announces New Appointments to its Management Team and Board of Directors (GlobeNewswire) +11.90%
Jan-05-22 08:00AM	Portage Biotech Announces Participation in January 2022 Investor Conferences (GlobeNewswire)
Nov-23-21 08:00AM	Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year (GlobeNewswire)
Nov-22-21 04:53PM	Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire) -7.06%
Nov-15-21 08:00AM	Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics INT230-6 (PORT-1) at November Scientific Conferences (GlobeNewswire)
Nov-10-21 08:00AM	Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment (GlobeNewswire) -6.53%

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

ATON

AlphaTON Capital Corp

Upgrade your FINVIZ experience